|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00556582 |
Purpose
RATIONALE: Gathering information about patients with a personal or family history of cancer associated with a virus may help doctors learn more about the disease.
PURPOSE: This clinical trial is studying patients with a personal or family history of cancer caused by a virus.
| Condition | Intervention |
|
Lymphoma Sarcoma Small Intestine Cancer Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
Procedure: biologic sample preservation procedure Procedure: biopsy Procedure: cytology specimen collection procedure Procedure: immunologic technique Procedure: study of high risk factors |
| MedlinePlus related topics: | Cancer Intestinal Cancer Lymphoma Soft Tissue Sarcoma |
| ChemIDplus related topics: | Salicylsalicylic acid Sodium salicylate |
| Study Type: | Observational |
| Official Title: | Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers |
| Estimated Enrollment: | 200 |
| Study Start Date: | December 1996 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: Patients undergo an interview, physical examination, and blood sample collection. Other clinically indicated biological samples, such as urine, sputum, saliva, tears, or semen or cervical, anal, oral, or nasal swabs, are collected. Skin testing with conventional, licensed antigens for assessment of cellular immunity may be performed, and skin lesions may be biopsied or excised. Tumor or other tissue biopsies may be obtained when biopsy or surgery is clinically indicated. The biological samples are frozen or preserved for current or future research studies.
Patients receive counseling relevant to the disease under study, and about the interim study results. Clinical referrals are made as needed.
Eligibility
| Ages Eligible for Study: | up to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Personal or family history of viral-associated neoplasia of an unusual type, pattern, or number including, but not limited to, the following:
Known or suspected factor(s) predisposing to neoplasia, including any of the following:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Contacts and Locations| United States, Maryland | |||||
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Recruiting | ||||
| Bethesda, Maryland, United States, 20892-1182 | |||||
| Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937 | |||||
| Principal Investigator: | James J. Goedert, MD | National Cancer Institute (NCI) |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
| Study ID Numbers: | CDR0000566031, NCI-97-C-0028 |
| First Received: | November 9, 2007 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00556582 |
| Health Authority: | Unspecified |
|
|
|
|
|
|